Literature DB >> 9422706

Renovasculopathies in elderly normotensives of Bombay, India.

R E Tracy1, D N Lanjewar, K G Ghorpade, A G Valand, S R Raghuwanshi.   

Abstract

In essential hypertension, specific vasculopathies distinguish the kidney of nephrosclerosis. The severity of renovasculopathy can be measured histologically at autopsy. A previously determined equation uses the measurements to calculate mean blood pressure levels. That equation did not encompass elderly subjects with minimal vasculopathy, because they were deficient in the previous data set. Such subjects were abundant in a series of 86 autopsies conducted at the J.J. Hospital in Bombay. That newly reviewed series now provides many instances of normotension accompanying minimal vasculopathy at ages greater than 40-50 years. These conditions are seldom observed in the U.S.A. The newly examined elderly normotensives manifest degrees of renovasculopathy equivalent to those of youthful normotensives with comparable blood pressure levels. The elderly subjects who escaped a rise of blood pressure with age were those with long delayed progression of renovasculopathy; this may be the explanation for avoidance of hypertension in old age. The outcome places the J.J. Hospital patients among the populations of the world with the slowest rates of progression of hypertension.

Entities:  

Mesh:

Year:  1997        PMID: 9422706     DOI: 10.1023/a:1008237409093

Source DB:  PubMed          Journal:  Geriatr Nephrol Urol        ISSN: 0924-8455


  3 in total

Review 1.  The aging kidney: a review -- part I.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Hypertensive renovasculopathies and the rise of blood pressure with age in Japan and USA.

Authors:  R E Tracy; T Ishii
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

3.  Histologically measured cardiomyocyte hypertrophy correlates with body height as strongly as with body mass index.

Authors:  Richard E Tracy; Gary E Sander
Journal:  Cardiol Res Pract       Date:  2011-06-08       Impact factor: 1.866

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.